Address: Leiden Bio Science Park Foundation
Poortgebouw Noord
Rijnsburgerweg 10
2333 AA Leiden ,Netherlands
Tel: + 31 (0)71 524 7555
Web: http://www.leidenbiosciencepark.nl/
Leiden Bio Science Park is the leading life sciences cluster in the Netherlands and ranks among the top five most successful science parks in Europe. It is fully dedicated to biomedical life sciences and offers opportunities for both start-ups and established companies.
The Leiden Bio Science Park is a well-equipped knowledge cluster with a large concentration of life science businesses, knowledge institutions and educational facilities, all supported by local, regional and national governments.
Dutch support for life sciences
The city of Leiden, the Province of South-Holland and the Dutch Ministry of Economic Affairs consider the Leiden Bio Science Park to be the life science hotspot of the Netherlands.
The life science sector remains high on Leiden’s municipal agenda, as it is a key to economic growth, employment and education. It is also supported at national level and by the EU.
EU chooses life science
Within the European Union (EU), life science represents an important pillar of the ambitious so-called Lisbon strategy, which was set out by the European Council in 2000. The strategy aims to make the EU the most competitive economy in the world and to achieve full employment by 2010. The EU supports the sector financially and has improved the life science business climate.
Dutch business climate excellent for life science
The Dutch government recognizes the economic value of life science and its potential for solving important global health issues. The ministry of Economic Affairs has supported the sector financially in the past few years and provided facilities via dedicated programs like ‘Biopartner’. In 2004, the government’s ‘Action Plan for Life Science’ simplified legislation to improve the business climate for life science. It is now considered one of the best in Europe.
Leiden – life meets science
To further strengthen Leiden’s bio-cluster, the local and regional governments, the relevant educational and research institutions and the business community have committed themselves to an action program under the motto Leiden – life meets science. This sets the agenda for the coming years and provides a basis for implementation and coordination of projects with financiers and governments
Thijs De Kleer, Managing Director, Saco de Visser, Director Cluster Development, discuss recent developments at the Netherlands largest science park and how Leiden has positioned itself as a leader in…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an…
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
See our Cookie Privacy Policy Here
